BIO-TECHNE Corp. 10-Q Summary: Quarter Ended March 31, 2026
Business Context and Reporting Period
This summary covers the unaudited quarterly report (Form 10-Q) for BIO-TECHNE Corp. for the quarter and nine months ended March 31, 2026. The Company develops, manufactures, and sells biotechnology reagents, instruments, and services for research and clinical diagnostic markets. Operations are reported in two segments: Protein Sciences and Diagnostics and Spatial Biology.
Key Financial Metrics
| Metric | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Net Sales | $311.4M | $316.2M | $893.8M | $902.7M |
| Gross Margin | $208.3M (66.9%) | $214.6M (67.9%) | $587.7M (65.7%) | $591.5M (65.5%) |
| Operating Income | $75.5M | $38.7M | $177.6M | $126.1M |
| Net Earnings | $51.0M | $22.6M | $127.2M | $91.1M |
| Diluted EPS | $0.32 | $0.14 | $0.81 | $0.57 |
| Cash from Operations (9M) | $196.7M (vs. $189.4M prior year) | |||
| Long-Term Debt | $200.0M (vs. $346.0M at June 30, 2025) | |||
| Cash & Equivalents | $209.8M |
Material Changes vs. Prior Period
- Revenue: Consolidated net sales decreased 2% in Q3 and 1% for the nine months ended March 31, 2026, compared to the prior year. Organic revenue declined 2% (Q3) and 1% (9M), offset by a favorable 2% foreign currency impact. The decline was driven by unfavorable volume and mix in the Protein Sciences segment, partially offset by growth in Diagnostics and Spatial Biology.
- Profitability: Operating income increased significantly (95% in Q3, 41% for 9M) primarily due to the absence of a $38.9 million litigation charge recorded in the prior year Q3 related to a former CEO arbitration award. SG&A expenses decreased 28% in Q3 and 13% for the nine months.
- Debt Reduction: The Company repaid $146.0 million of long-term debt during the nine months ended March 31, 2026, reducing the balance from $346.0 million to $200.0 million.
- Restructuring: The Company recorded $2.8 million in restructuring charges for Q3 2026, primarily related to asset impairments and severance. This compares to $0.7 million in Q3 2025.
Guidance, Outlook, and Risks
- Tax Outlook: The Company expects the consolidated income tax rate for the remainder of fiscal 2026 to range from 25% to 29%, excluding discrete items. The forecasted tax rate before discrete items is 26.9%.
- Capital Expenditures: Capital expenditures for the remainder of fiscal 2026 are expected to be approximately $7 million, funded by available cash and operating cash flows.
- Dividends: A quarterly cash dividend of $0.08 per share was declared, payable May 29, 2026.
- Wilson Wolf Acquisition: The Company is obligated to acquire the remaining 80.1% of Wilson Wolf Corporation by December 31, 2027, or earlier if certain revenue/EBITDA milestones are met. The estimated payment is approximately $1 billion plus potential contingent consideration. As of March 31, 2026, the second milestone has not been met.
- Risks: Key risks include integration of acquired businesses, supply chain challenges, foreign currency fluctuations, and the outcome of ongoing legal proceedings, though no material adverse legal proceedings were identified as of May 6, 2026.
Investor Verification Checklist
- Organic Growth Drivers: Verify the specific product mix and volume trends within the Protein Sciences segment causing the organic revenue decline.
- Wilson Wolf Milestones: Monitor Wilson Wolf's revenue and EBITDA performance to assess the timing and potential acceleration of the ~$1 billion acquisition obligation.
- Restructuring Progress: Track the execution of manufacturing optimization initiatives and associated cost savings versus incurred charges.
- Debt Capacity: Confirm the utilization of the $1 billion revolving credit facility (currently $800M available) and its impact on liquidity given the future Wilson Wolf payment.
- Non-GAAP Reconciliations: Review the reconciliation of Adjusted Net Earnings ($82.8M for Q3) to GAAP Net Earnings to understand the impact of excluded items like stock-based compensation and amortization.